FDA — authorised 5 October 1962
- Marketing authorisation holder: ASPEN GLOBAL INC
- Status: approved
🇺🇸 Nandrolone Decanoate in United States
FDA authorised Nandrolone Decanoate on 5 October 1962
Marketing authorisations
FDA — authorised 5 October 1962
- Application: NDA013132
- Marketing authorisation holder: WOODWARD SPECL
- Local brand name: DECA-DURABOLIN
- Indication: INJECTABLE — INJECTION
- Status: approved
FDA — authorised 17 May 1983
- Application: ANDA086385
- Marketing authorisation holder: WATSON LABS
- Local brand name: NANDROLONE DECANOATE
- Indication: INJECTABLE — INJECTION
- Status: approved
FDA — authorised 17 May 1983
- Application: ANDA086598
- Marketing authorisation holder: WATSON LABS
- Local brand name: NANDROLONE DECANOATE
- Indication: INJECTABLE — INJECTION
- Status: approved
FDA — authorised 14 October 1983
- Application: ANDA088317
- Marketing authorisation holder: ABRAXIS PHARM
- Local brand name: NANDROLONE DECANOATE
- Indication: INJECTABLE — INJECTION
- Status: approved
FDA — authorised 5 December 1983
- Application: ANDA088128
- Marketing authorisation holder: WATSON LABS
- Local brand name: NANDROLONE DECANOATE
- Indication: INJECTABLE — INJECTION
- Status: approved
FDA — authorised 17 March 1989
- Application: ANDA088290
- Marketing authorisation holder: ABRAXIS PHARM
- Local brand name: NANDROLONE DECANOATE
- Indication: INJECTABLE — INJECTION
- Status: approved
FDA — authorised 30 August 2010
- Application: ANDA091252
- Marketing authorisation holder: AM REGENT
- Local brand name: NANDROLONE DECANOATE
- Indication: INJECTABLE — INJECTION
- Status: approved
FDA
- Application: ANDA089249
- Marketing authorisation holder: QUAD PHARMS
- Local brand name: NANDROLONE DECANOATE
- Indication: Injectable — Injection
- Status: approved
FDA
- Application: ANDA089248
- Marketing authorisation holder: QUAD PHARMS
- Local brand name: NANDROLONE DECANOATE
- Indication: Injectable — Injection
- Status: approved
FDA
- Application: ANDA089250
- Marketing authorisation holder: QUAD PHARMS
- Local brand name: NANDROLONE DECANOATE
- Indication: Injectable — Injection
- Status: approved
FDA
- Application: ANDA088554
- Marketing authorisation holder: WATSON LABS
- Local brand name: NANDROLONE DECANOATE
- Indication: INJECTABLE — INJECTION
- Status: approved
FDA
- Application: ANDA087519
- Marketing authorisation holder: EPIC PHARMA LLC
- Local brand name: NANDROLONE DECANOATE
- Indication: INJECTABLE — INJECTION
- Status: approved
FDA
- Application: ANDA087598
- Marketing authorisation holder: WATSON LABS
- Local brand name: NANDROLONE DECANOATE
- Indication: INJECTABLE — INJECTION
- Status: approved
FDA
- Application: ANDA087599
- Marketing authorisation holder: WATSON LABS
- Local brand name: NANDROLONE DECANOATE
- Indication: INJECTABLE — INJECTION
- Status: approved
Nandrolone Decanoate in other countries
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Other Hematology approved in United States
Frequently asked questions
Is Nandrolone Decanoate approved in United States?
Yes. FDA authorised it on 5 October 1962; FDA authorised it on 5 October 1962; FDA authorised it on 17 May 1983.
Who is the marketing authorisation holder for Nandrolone Decanoate in United States?
ASPEN GLOBAL INC holds the US marketing authorisation.